BAJAJ BROKING

Notification close image
No new Notification messages
card image
Oswal Pumps IPO is Open!
Apply for the Oswal Pumps IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Dr. Reddy’s Q4 Results FY24-25, Revenue up 17%, Net Profit at ₹5,724 Cr

Key Highlights/Quick Insights

  • FY25 Revenue: ₹32,553 Cr, up 17% YoY

  • FY25 Net Profit: ₹5,724 Cr, up 2.8% YoY

  • Q4 FY25 Revenue: ₹8,506 Cr, up 20% YoY

  • Q4 FY25 Net Profit: ₹1,587 Cr vs ₹1,307 Cr in Q4 FY24

  • FY25 EBITDA: ₹7,184 Cr

  • EPS (FY25): ₹67.88 per share

DR. REDDY S LABORATORIES

Trade

1362.5-0.19 (-0.01 %)

Updated - 13 June 2025
1366.80day high
DAY HIGH
1345.00day low
DAY LOW
1419556
VOLUME (BSE)

Quarterly – Dr. Reddy’s Q4 Results FY24-25

Particulars

Q4 FY25 (₹ Cr)

Q3 FY25 (₹ Cr)

Q4 FY24 (₹ Cr)

Revenue from Operations

8,506

8,359

7,083

Cost of Revenues

3,780

3,453

2,935

Gross Profit

4,726

4,906

4,148

SG&A Expenses

2,405

2,412

2,048

R&D Expenses

726

666

688

Impairment of Assets

77

(0.04)

17

Other Income, Net

(247)

(44)

(66)

Total Operating Expenses

2,962

3,033

2,652

Operating Profit

1,765

1,872

1,496

Finance Income

301

468

162

Finance Expense

(66)

(82)

(59)

Profit Before Tax

2,005

1,874

1,602

Tax Expense

418

470

295

Net Profit (PAT)

1,587

1,403

1,307

EPS (Basic, ₹)

19.13

16.94

15.70

EPS (Diluted, ₹)

19.11

16.94

15.67

Segment Highlights

Segment

FY25 Revenue (₹ Cr)

FY24 Revenue (₹ Cr)

FY25 Segment Profit (₹ Cr)

Pharmaceutical Services & APIs

4,324

4,058

916

Global Generics

28,953

24,545

17,906

Others

297

312

17

Total Revenue

33,424

28,915

19,074

Less: Inter-segment Revenue

(851)

(1,054)

Net Consolidated Revenue

32,573

27,861

  • Global Generics accounted for 89% of total revenue

  • API business recorded healthy 6.5% growth

  • Other segments remained stable

Sector Expectations for Dr. Reddy’s Q4 Results FY24-25

Analysts expected mid-teen revenue growth, led by strong US generics and Europe sales. Operating leverage and price stability supported margin expansion, while R&D investment impacted short-term profitability. Results were in line with street estimates.

Management Commentary

Commenting on the results, Co-Chairman & MD, G V Prasad said: "We achieved double-digit growth across our businesses, driven by successful product launches, increased revenues from key products in the U.S. and the integration of the acquired NRT business."

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

10 lakh+ Users

icon-with-text

4.4 App Rating

icon-with-text

4 Languages

icon-with-text

₹5100+ Cr MTF Book

icon-with-text